CTKBNasdaqLaboratory Analytical InstrumentsFiscal year ends December 31
Cytek Biosciences, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$5.25+0.00 (0.00%)
Close on Oct 19, 2026
- Market cap
- $679.67M
- P/E (TTM)
- –
- Dividend yield
- –
Cytek Biosciences, Inc. revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product | $32.56M | $28.78M | $46.59M | $38.11M | $31.42M | $28.11M | $45.02M | $39.54M | $34.58M | $34.12M | $46.65M | $38.44M | 67.6% | +3.6% |
| Service | $15.58M | $15.36M | $15.55M | $14.18M | $14.19M | $13.35M | $12.46M | $11.96M | $12.04M | $10.74M | $11.58M | $9.56M | 32.4% | +9.8% |
By region
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $28.22M | $24.39M | $25.62M | $27.20M | $23.89M | $18.54M | $24.51M | $24.35M | $22.39M | $21.36M | $27.14M | $26.79M | 58.6% | +18.1% |
| EMEA | $11.30M | $10.77M | $19.62M | $12.39M | $12.31M | $11.57M | $16.21M | $17.23M | $13.77M | $15.13M | $19.71M | $12.92M | 23.5% | -8.2% |
| APAC | $7.92M | $7.75M | $13.18M | $11.14M | $7.87M | $8.89M | $11.50M | $8.94M | $8.98M | $6.35M | $9.53M | $6.76M | 16.4% | +0.6% |
| China | $4.80M | $3.60M | $6.30M | $5.30M | – | $5.30M | – | – | – | $3.20M | – | – | 10.0% | – |
| Other | $701.00K | $1.23M | $3.72M | $1.56M | $1.53M | $2.47M | $5.26M | $979.00K | $1.47M | $2.03M | $1.86M | $1.53M | 1.5% | -54.2% |
From the segment and revenue-disaggregation notes of Cytek Biosciences's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.